Meeting
2024 ASCO Annual Meeting
Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001).
Authors
Zhicheng Lai
Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
Zhicheng Lai , Anna Kan , MinKe He , Zefeng Du , Ming Shi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02856126
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4113)
DOI
10.1200/JCO.2024.42.16_suppl.4113
Abstract #
4113
Poster Bd #
93
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Effectiveness of transarterial chemoembolization combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma.
First Author: Fei Cao
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world survival outcomes and treatment patterns in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the OREIOS study.
First Author: Stephen Chan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The efficacy and safety of transarterial chemoembolization combined with cadonilimab and lenvatinib for unresectable hepatocellular carcinoma: A phase II clinical trial.
First Author: Guo Liang
Poster
2023 ASCO Annual Meeting
NeoTACE: A multicenter, randomized study evaluating the efficacy and safety of neoadjuvant HAIC for TACE plus donafenib in BCLC B stage hepatocellular carcinoma outside of up-to-seven.
First Author: Xiaodong Wang